Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinician-reviewed guide to the legal status of compounded semaglutide (Ozempic), FDA shortage declarations, 503A/503B pharmacy rules, and what changes mean for patients in 2026.
Read clinical reviewA clinical comparison of how the FDA and EMA regulate Ozempic (semaglutide), covering approval timelines, label differences, boxed warnings, post-market surveillance, and safety monitoring frameworks.
Read clinical reviewA clinical review of Ozempic (semaglutide) FDA Adverse Event Reporting System signals, label updates, and post-market safety data through 2026.
Read clinical reviewA clinical review of Ozempic (semaglutide) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and ongoing label expansions.
Read clinical reviewEvery FDA label change to Ozempic (semaglutide 0.5-2.0 mg) from 2020 through 2026, including new warnings, dose expansions, and post-market safety signals.
Read clinical reviewA clinical review of Ozempic (semaglutide) regulatory history, current FDA label, post-market safety surveillance, and the next-generation GLP-1 pipeline from Novo Nordisk and competitors.
Read clinical review